Vor Biopharma (VOR) Enterprise Value (2020 - 2026)
Vor Biopharma (VOR) reported Enterprise Value of -$491.5 million for Q1 2026, down 718.73% year-over-year from $79.4 million in Q1 2025, and down 7.98% on a QoQ basis from -$455.2 million in Q4 2025.
Vor Biopharma (VOR) has 7 years of Enterprise Value data on file, last reported at -$491.5 million in Q1 2026.
- Quarterly Enterprise Value fell 718.73% year-over-year to -$491.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$491.5 million (down 718.73% YoY) and the FY2025 annual result came in at -$455.2 million, down 395.19% from the prior year.
- Enterprise Value declined to -$491.5 million in Q1 2026 per VOR's latest filing, from -$455.2 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$60.0 million in Q1 2025 and bottomed at -$491.5 million in Q1 2026.
- The 5-year median for Enterprise Value is -$160.1 million (2023), against an average of -$183.5 million.
- The widest annual swing landed in 2024, when Enterprise Value jumped 60.77%; it then sank 718.73% in 2026.
- Tracing VOR's Enterprise Value over 5 years: stood at -$230.2 million in 2022, then surged by 40.42% to -$137.2 million in 2023, then surged by 32.99% to -$91.9 million in 2024, then slumped by 395.19% to -$455.2 million in 2025, then retreated by 7.98% to -$491.5 million in 2026.
- Per Business Quant, the three latest VOR Enterprise Value figures stand at -$491.5 million (Q1 2026), -$455.2 million (Q4 2025), and -$170.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -3.01 Bn |
| 10 | Vor Biopharma | 628.83 Mn | 628.83 Mn | - | -491.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -491.53 Mn |
| Dec 31, 2025 | -455.21 Mn |
| Sep 30, 2025 | -170.46 Mn |
| Jun 30, 2025 | -200.57 Mn |
| Mar 31, 2025 | -60.04 Mn |
| Dec 31, 2024 | -91.93 Mn |
| Sep 30, 2024 | -62.81 Mn |
| Jun 30, 2024 | -85.94 Mn |
| Mar 31, 2024 | -107.48 Mn |
| Dec 31, 2023 | -137.18 Mn |
| Sep 30, 2023 | -160.10 Mn |
| Jun 30, 2023 | -186.90 Mn |
| Mar 31, 2023 | -210.20 Mn |
| Dec 31, 2022 | -230.25 Mn |
| Sep 30, 2022 | -136.07 Mn |
| Jun 30, 2022 | -151.09 Mn |
| Mar 31, 2022 | -181.62 Mn |
| Dec 31, 2021 | -207.47 Mn |
| Sep 30, 2021 | -225.97 Mn |
| Jun 30, 2021 | -244.63 Mn |
| Mar 31, 2021 | -262.57 Mn |
| Dec 31, 2020 | -48.54 Mn |
| Sep 30, 2020 | -63.60 Mn |
| Jun 30, 2020 | -72.91 Mn |